MAP2K7 and myeloproliferative disorder: This observation is similar to those seen with MPN-bearing KRASG12D mice that have been treated with MEK, PI3K or AKT small molecule inhibitors, whereby this non-myeloid malignancy appears to be the primary cause of death in a small percentage of KRASG12D mice treated with those targeted therapeutics [19, 20].